COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04611802 Novavax Dunkle L M, N Engl J Med, 2021 Full text Commentary |
Protein subunit |
NVX-CoV2373 |
Placebo |
RCTPhase 3 | Healthy adults in 113 sites in the USA and 6 in Mexico | N= 29949 |
Some concerns Details |
|
|
NCT04368988 Novavax Formica N, PLoS Med, 2021 Full text Commentary |
Protein subunit |
NVX-CoV2373 5mcg D0/21 NVX-CoV2373 5mcg D0/Placebo D21 NVX-CoV2373 25mcg D0/21 NVX-CoV2373 25mcg D0/Placebo D21 |
Placebo D0/D21 |
RCTPhase 2 | Healthy adults (stable comorbidities permitted) aged 18-84 years at 17 centers in Australia and USA | N= 1288 |
Some concerns Details |
|
|
NCT04583995; EudraCT 2020-004123-16 Novavax Heath P, Clin Infect Dis, 2022 Full text Commentary |
Protein subunit |
NVX-CoV2373 5 mcg D0/21 |
Placebo D0/21 |
RCTPhase 3 | Adults 18 to 84 years old who were healthy or had stable chronic medical conditions with no history of COVID-19 at 33 centres in the UK. | N= 15,185 |
Some concerns Details |
|
|
NCT04368988 Novavax Keech C, N Engl J Med, 2020 Full text Commentary |
Protein subunit |
NVX-CoV2373 25mcg D0/21 NVX-CoV2373 5mcg/Matrix-M1 50 mcg D0/21 NVX-CoV2373 25mcg/Matrix-M1 50 mcg D0/21 NVX-CoV2373 25mcg/Matrix-M1 50 mcg D0/ Placebo D21 |
Placebo D0/21 |
RCTPhase 1 | Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia. | N= 134 |
Some concerns Details |
|
|
NCT04533399; PACTR202009726132275 Novavax Madhi S, Lancet HIV, 2022 Full text Commentary |
Protein subunit |
5mcg NVX-CoV2373 with 50 mcg Matrix-M1 adjuvant |
Placebo |
RCTPhase 2 | HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa | N= 4419 |
Some concerns Details |
|
|
NCT04712110 Novavax Masuda T, Vaccine, 2022 b Full text Commentary Commentary Commentary |
Protein subunit |
NVX-CoV2373 |
Placebo |
RCTPhase 1-2 | Healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments at 2 centers in Japan. | N= 200 |
Some concerns Details |
|